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Background: Endothelial colony-forming cells (ECFCs), also termed late outgrowth endothelial cells, are a well-
defined circulating endothelial progenitor cell type with an established role in vascular repair. ECFCs have clear
potential for cell therapy to treat ischaemic disease, although the precise mechanism(s) underlying their response
to hypoxia remains ill-defined.
Methods: In this study, we isolated ECFCs from umbilical cord blood and cultured them on collagen. We defined
the response of ECFCs to 1% O2 exposure at acute and chronic time points.
Results: In response to low oxygen, changes in ECFC cell shape, proliferation, size and cytoskeleton phenotype
were detected. An increase in the number of senescent ECFCs also occurred as a result of long-term culture in 1%
O2. Low oxygen exposure altered ECFC migration and tube formation in Matrigel®. Increases in angiogenic factors
secreted from ECFCs exposed to hypoxia were also detected, in particular, after treatment with placental growth
factor (PlGF). Exposure of cells to agents that stabilise hypoxia-inducible factors such as dimethyloxalylglycine
(DMOG) also increased PlGF levels. Conditioned medium from both hypoxia-treated and DMOG-treated cells
inhibited ECFC tube formation. This effect was reversed by the addition of PlGF neutralising antibody to the
conditioned medium, confirming the direct role of PlGF in this effect.
Conclusions: This study deepens our understanding of the response of ECFCs to hypoxia and also identifies a
novel and important role for PlGF in regulating the vasculogenic potential of ECFCs.
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Since the first description of endothelial progenitor
cells (EPCs) in 1997 as bone marrow-derived vascular
precursors with reparative potential [1], there has been
considerable interest in their utility for cell-based therapy
of ischaemic vasculopathies. “EPC” refers to a broad range
of vascular progenitors characterised using diverse cell
surface markers and functional endpoints. Endothelial
colony-forming cells (ECFCs), also known as late EPCs or* Correspondence: d.brazil@qub.ac.uk
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lating EPCs with the ability to differentiate into endothe-
lial cells and mediate vascular repair [2]. When isolated,
ECFCs have significantly higher proliferative capacity
compared with mature endothelial cells, and they main-
tain their endothelial progenitor phenotype during
long-term ex-vivo expansion [3]. ECFCs are also cap-
able of supporting vascular repair in vivo by integration
into pre-existing vasculature, significantly reducing areas
of ischaemia in murine models of retinopathy, myocardial
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treat ischaemic diseases by aiding vascular repair as well
as establishing new vasculature [5]. However, the function
and number of ECFCs and other EPC subtypes have been
reported to be impaired in a range of vascular disease
states such as diabetes [6, 7], cardiovascular disease [8],
preeclampsia [9] and vascular development in premature
infants [10]. The number and function of ECFCs has also
been shown to be impaired in low birth weight infants
[11], a patient cohort at risk of retinal ischaemia in infancy
and cardiovascular disease in adulthood. Accelerated sen-
escence in premature ECFCs as a result of decreased
SIRT1 expression was also demonstrated recently [12].
Therefore, it is important to understand what happens
when ECFCs enter a hypoxic environment and what mo-
lecular cues are required to stimulate ECFC-mediated vas-
cular repair.
Placental growth factor (PlGF) is a member of the
vascular endothelial growth factor (VEGF) family that
has been demonstrated to promote angiogenesis both
independently and synergistically via heterodimer for-
mation with VEGF-A to activate Flt1/VEGF receptor-1
signalling [13]. PlGF also binds to the neuropilin-1/
VEGF165 receptor and stimulates angiogenesis [14].
Since its discovery in 1991 [15], PlGF has been associated
with a number of disease states [16] including ischaemia
[17], cardiovascular disease [18], cancer [19], arthritis [20]
and preeclampsia [21]. Recent reports have revealed that
there is increased secretion of PlGF from ECFCs isolated
from end-stage renal failure patients [22] while in-vitro
exposure to PlGF can enhance tubulogenic function in
ECFCs [18]. These findings suggest that PlGF may have
an important if ill-defined role in normal ECFC vasore-
parative function. The signalling and functional re-
sponses of ECFCs exposed to PlGF remains to be
elucidated, especially in the context of vascular insuffi-
ciency and hypoxia encountered by cells as they home
to areas of localised tissue damage [23]. In this study,
we define the effects of acute and chronic hypoxia on
ECFCs in the absence of other confounding factors. In
response to low oxygen, we observed changes in ECFC
cell size, shape, cytoskeletal structure and proliferative
potential. Low oxygen altered ECFC scratch wound
repair and in-vitro tube formation in Matrigel®. Of
particular interest, we observed increased levels of PlGF
secreted from ECFCs exposed to hypoxia and dimethylox-
alylglycine (DMOG), a HIF stabilising agent. Conditioned
medium from these cells inhibited tube formation in
fresh ECFCs. This effect was reversed by neutralising
antibodies against PlGF, confirming its central role in
this effect. Improved knowledge of how ECFCs respond
to low oxygen in vitro will aid understanding of how
they may adapt their function to aid vascular repair in
ischaemic diseases.Methods
ECFC isolation, in-vitro culture and hypoxia exposure
ECFCs were isolated from umbilical cord blood of full-
term neonates. Mononuclear cells (MNCs) were ob-
tained by density gradient fractionation, re-suspended
in complete medium (EGM-2; Lonza) supplemented
with 10% FBS and seeded on 24-well culture plates pre-
coated with rat tail collagen type 1 (BD Biosciences) at a
density of 1 × 107 cells/ml. Colonies typically appeared
within 2–3 weeks, and ECFC clones were typically cul-
tured for >20 passages. A humidified, temperature-
controlled hypoxia chamber (Coy Laboratories) was used
to maintain cells in 1% O2. Culture media were precondi-
tioned to 1% O2 prior to use to ensure instantaneous
hypoxia exposure and the temperature was maintained at
37 °C. A Casy cell counter-analyser (Roche) was used for
cell counts, viability and cellular size assessment.
Immunocytochemistry
Cells were fixed in 4% (w/v) paraformaldehyde for 20 min
at room temperature. Following PBS washes, cells were
permeabilised with 0.1% Triton X-100 for 10 min at RT
and then blocked in 1% bovine serum albumin (BSA) for
2 h in PBS before overnight incubation in primary anti-
body at 4 °C. After washing with PBS, cells were incubated
with appropriate secondary antibody for 1 h at RT and
imaged under a confocal fluorescence scanning micro-
scope (Nikon). Primary antibodies phalloidin (Invitrogen)
and vinculin (Sigma-Aldrich) were used to stain F-actin
and focal adhesion complexes respectively. Anti-mouse
Alexa Fluor 568 IgG (Invitrogen) was used as secondary
antibody. Mounting medium contained the nuclear stain
DAPI (Vectashield; Vector Laboratories).
Flow cytometry
For staining, 5 × 105 ECFCs were used per sample. Cells
were filtered using cell strainers with a 35-μm nylon mesh
(BD Falcon; BD Biosciences), re-suspended in 100 μl PBS
buffer and incubated with respective antibodies for 45 min
at 4 °C. Antibodies reactive to CD31 (platelet endothelial
cell adhesion molecule (PECAM)), CD45 (protein tyrosine
phosphatase receptor type C), CD14 (monocyte differenti-
ation antigen; eBioscience) and CD146 (melanoma cell
adhesion molecule; BD Biosciences) were utilised. After
staining, cells were washed in PBS and finally resuspended
in 1 ml PBS for analysis using an Attune® Acoustic Focus-
ing Flow Cytometer (Invitrogen Life Technologies). At
least 20,000 events were acquired for each sample. Re-
spective isotype controls were used to determine accurate
settings for data analysis.
Protein extraction and western blotting
Protein was extracted from ECFCs using ice-cold
RIPA containing protease and phosphatase inhibitors
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protein was resolved by electrophoresis through 10%
SDS polyacrylamide gel and electro-transferred onto
PVDF membrane (Millipore). The membranes were
blocked for 1 h at RT with 3% (w/v) non-fat dry milk
in Tris-buffered saline with 0.1% Tween-20 (TBS-T).
After blocking, the membranes were incubated overnight
at 4 °C with primary antibodies reactive to HIF-1α
(#610958; BD Biosciences) and HIF-2α (R&D Systems).
After three washes with TBS-T, the membranes were
incubated for 1 h with their respective HRP-conjugated
secondary antibodies (Santa Cruz). Three TBS-T washes
were carried out before the protein bands were detected
using ECL (Merck Millipore). Membranes were re-probed
with β-actin (Cell Signaling Technology) as a housekeep-
ing gene to ensure equal loading.Scratch wound repair assay
ECFCs were grown on collagen-coated 24-well plates until
confluent. The monolayer was then scratched using a
p200 pipette tip to create a wound. After gentle washing
with PBS, the growth media was changed to serum-free
EGM-2. The scratched area was imaged using ImageJ ana-
lysis software, and the wound distance was measured at
the beginning (T0) and end of the experiment (TX). The
following formula was used to convert the migrated area
of the scratch wound into a percentage:
% of wound closure ¼ T0 – TX ¼ X = T0100:
Cell viability
ECFC viability was determined using the Cell Counting
Kit-8 (CCK-8; Sigma) as per the manufacturer’s instruc-
tions. Cells were seeded in 96-well collagen-coated plates
(1 × 104 cells/well). Cells were treated for 24 h with
100 ng/ml human recombinant PlGF (R&D Systems) or
vehicle (4 mM HCl 0.1% BSA). Absorbance was measured
at 450 nm using an Omega plate reader.Proteome profiling
A proteome profiler human angiogenesis array (R&D
Systems) was used to analyse the secretion of angiogenic
cytokines from ECFCs. Cells were maintained in serum-
free medium in 21 and 1% O2 for 24 h, in accordance
with the manufacturer’s instructions. ImageJ image ana-
lysis software was used to calculate densitometry and all
results were normalised to a positive control. PlGF levels
in cell culture supernatant were measured using a PlGF-
specific ELISA (R&D Systems) according to the manu-
facturer’s instructions.DMOG treatment
ECFCs were grown in complete media (EGM-2; Lonza)
and treated with either dimethylsulfoxide (DMSO, ve-
hicle) or 1 mM DMOG (Sigma-Aldrich) for 24 h. At
harvest, media were removed and stored at –80 oC for
analysis, after which the cells were washed in ice-cold
PBS prior to further analysis by western blot analysis.
PlGF levels in cell culture supernatant were measured
using a PlGF-specific ELISA (R&D Systems) according
to the manufacturer’s instructions.
Tubulogenesis assay
ECFCs were labelled using a fluorescence membrane la-
belling kit (PKH; Sigma) or Calcein AM dye (Molecular
Probes) according to the manufacturer's protocol.
Between 8 × 104 and 1 × 105 labelled ECFCs were re-
suspended in basement membrane matrix (Matrigel®;
BD Biosciences). Fifty-microlitre aliquots were spotted
onto four-well plates. After polymerisation, the spots
were covered in endothelial cell growth medium
(EGM-2; Lonza) or a 1:1 ratio of EGM-2 and condi-
tioned media. Wells were assessed for the presence of
tube-like structures after 24, 48 and 72 h, and were im-
aged using a confocal scanning microscope (Nikon).
For PlGF neutralising experiments, ECFCs (7.5 × 105
cells) were mixed with conditioned medium collected
from previously treated ECFCs exposed to vehicle or
DMOG (1 mM) and resuspended in basement mem-
brane Matrix (Matrigel®). Next, 50-μl aliquots were
spotted onto a 24-well plate and allowed to polymerise.
After polymerisation, spots were covered in conditioned
medium from vehicle or DMOG-treated cells in the pres-
ence of a PlGF neutralising antibody (MAB264; R&D
Systems) or an isotype IgG control (Sigma). Matrigel®
spots were labelled with Calcein AM dye (Molecular
Probes) prior to imaging. Wells were assessed for the
presence of tube-like structures after 24 h, and imaged
using a confocal scanning microscope (Nikon). The vascu-
lar tube area was quantified using NIS Elements software
(Nikon).
Reverse-transcription and real-time PCR
Total RNA was isolated using an RNeasy Mini Kit
(Qiagen). cDNA was synthesised from 500 ng RNA using
Superscript III (Invitrogen). Semi-quantitative real-time
PCR was performed using gene-specific Real Time ready
Custom Single assays for ANGPTL4, SLC2A1 and house-
keeping genes β-actin and 18S (Roche). Relative quantita-
tive values were obtained using the ΔΔCt method.
β-Galactosidase activity
ECFCs were grown on collagen-coated glass coverslips
prior to senescence analysis. β-Galactosidase activity was
detected using the Senescence β-galactosidase Staining
Fig. 1 HIF-1α stabilisation in ECFCs occurs rapidly at 1% O2. ECFCs were grown in 12% FCS-supplemented EBM-2 medium. a ECFCs were
cultured at the indicated oxygen tension for 5 h. Protein lysates were probed using HIF-1α (top panel), with β-actin included as a loading control
(bottom panel). b ECFCs were cultured in full EBM medium at 1% O2 for the indicated time range, starting at 5 min (5’) and ending at 240 min
(240’). Cells were lysed and protein lysates were probed with HIF-1α (top panel), with β-actin included as a loading control (bottom panel) (n = 3).
HIF-1α hypoxia inducible factor 1 alpha
Fig. 2 ECFC responses to 1% O2. ECFCs were grown in 12% FCS-supplemented EBM-2 medium and maintained in either 21 or 1% O2 for the
indicated times. a Protein lysates isolated from time-matched ECFCs grown under normal conditions (21% O2) or hypoxic conditions (1% O2)
were probed with HIF-1α (top panel) or HIF-2α, with β-actin included as a loading control (bottom panel). b. ECFCs cultured at 21 or 1% for 5 h
were permeabilised and incubated with antibodies reactive to HIF-α (red) and DAPI to stain the nuclei (blue). Scale bar: 50 μM. c Real-time PCR
was carried out on cDNA generated from ECFCs incubated in 1% O2 for the indicated times. Levels of HIF-1 responsive genes ANGPTL4 and
SLC2A1 were measured, and normalised to the mean of two housekeeping genes (18S and β-actin). The ΔΔCt subtractive method was used to
compare between treatments, with 21% O2 as the calibrator. Fold-changes compared with 21% O2 were calculated. Data plotted as mean fold-
change ± SD. *p < 0.05 (n = 5). HIF-1α hypoxia inducible factor 1 alpha (Colour figure online)
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facturer’s instructions. The cell monolayer was imaged
using a phase contrast microscope (Nikon). The percent-
age of positively stained cells was quantified using Ima-
geJ image analysis software.
Statistical analysis
Data were analysed using Student’s two-tailed paired or
unpaired t test or ANOVA and were plotted as mean ±
standard deviation (SD) unless otherwise indicated.
Results
ECFCs were isolated from umbilical cord blood of normal
term infants as described previously [24]. The endothelial
character of these cells was confirmed by the expression
of PECAM (CD31) and melanoma metastasis-associated
surface molecule (MUC18, CD146) (Additional file 1:
Figure S1). In addition, isolated ECFCs did not express the
leukocyte markers CD45 and the myeloid marker CD14,
which confirmed that these cells were not hematopoietic
in nature (Additional file 1: Figure S1). To examine the
effects of low oxygen on these cells, ECFCs were grown in
a range of oxygen tensions from 21% (atmospheric oxygen,
760 mmHg) to 10, 5, 3 and 1% (36 mmHg, Fig. 1a). HIF-
1α immunoreactivity was only detected at ≤3% O2, with
the highest levels of HIF-1α detected at 1% (Fig. 1a). The
inhibition of prolyl-hydroxylases and accumulation of
cytoplasmic HIF-1α at 1% O2 was extremely rapid, and
was detected within 5 min of hypoxia exposure (Fig. 1b).Fig. 3 Hypoxia induces actin rearrangement and stress fibre formation in E
medium and maintained in either 21 or 1% O2 for 24 h. ECFCs were staine
(red) to identify focal adhesions and DAPI to stain the nuclei (blue). i, iv 40 ×
marker. ii, v Magnified area depicted in iii and vi. Actin stress fibres (green) a
(iii, vi). iii, vi Scale bar: 25 μm size marker (n = 3)A time-dependent increase in HIF-1α accumulation oc-
curred in ECFCs, with the strongest accumulation present
after 4 h (240 min) of hypoxia exposure. Based on these
data, all subsequent hypoxia exposure experiments were
carried out at 1% O2 for a minimum of 4–5 h.
Accumulation of both HIF-1α and HIF-2α isoforms
were observed in ECFCs grown in 1% O2 for 8, 24 and
48 h (Fig. 2a). In comparison with ECFCs grown in 21%
O2 (160 mmHg), cells grown in 1% O2 demonstrated a
marked increase in HIF-1α immunoreactivity in the cyto-
sol, with punctate staining in the nuclei evident at the 5 h
time point (Fig. 2b). This suggested that the HIF-1α sub-
unit was translocating to the nucleus as part of the typical
transcriptional response to hypoxia [25]. This was further
corroborated by the increased expression of HIF-1α regu-
lated transcripts ANGPTL4 and SLC2A1 (also known as
GLUT1) in ECFCs grown in 1% O2 (Fig. 2c). Thus, expos-
ure to low oxygen concentrations induces a typical “hyp-
oxia” response in terms of HIF-1α transcription factor
accumulation and gene transcription in ECFCs.
ECFC exposure to hypoxia induced the formation of
actin stress fibres, with cells displaying a more organised,
linear arrangement of F-actin (Fig. 3ii, v). Vincullin stain-
ing also revealed the appearance of focal adhesions in
ECFCs grown in 1% O2, at the terminal ends of the stri-
ated F-actin fibres (Fig. 3vi). These data suggest that low
oxygen concentrations triggered cytoskeletal changes in
ECFCs suggestive of cellular stress and an adaption to the
hypoxic environment by strengthening their attachmentCFCs. The ECFCs were grown in 12% FCS-supplemented EBM-2
d with phallodin to identify filamentous actin (F-actin, green), vincullin
magnification, ii, v 60 ×magnification. i, ii, iv, v Scale bars: 50 μm size
nd focal adhesions (red) are evident in a single cell grown in 1% O2
Fig. 4 Long-term exposure of ECFCs to hypoxia induces partial senescence. a ECFCs cultured at 21% O2 (open circles) or 1% O2 (filled circles) for
the indicated times. At each passage, cells were counted using a Casy cell counter. b Number of viable cells after 10-day culture in 21% O2
(empty bars) versus 1% O2 (filled bars). Cell numbers plotted as mean number of viable cells ± SD. *p < 0.05. c Diameter of cells in culture after 10-day
maintenance in 21% O2 (empty bars) versus 1% O2 (filled bars). Data plotted as mean cell diameter (μm) ± SD. *p < 0.05. d ECFCs in culture
were subjected to SA-β-galactosidase staining after 10-day hypoxia exposure (1% O2) together with time-matched normoxia controls (21%
O2). Representative images using bright-field microscopy, magnification 20 ×. e Number of SA-β-galactosidase-positive ECFCs in 21% (open
bars) and 1% O2 (filled bars) counted and expressed as a percentage of total cells. Data plotted as mean percentage ± SD. *p < 0.05 (n = 3)
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effect of low oxygen on ECFC phenotype, cells were main-
tained in 1% O2 for up to 18 days. Chronic hypoxia re-
duced ECFC cell doubling and viability (Fig. 4a, b).
Consistent with the cytoskeletal changes seen after 48 h,
ECFC cell size increased after culture in 1% O2 for 10 days
(Fig. 4c). The number of β-galactosidase-positive ECFCs
increased significantly after long-term culture in 1% O2,
suggestive of a senescence-like phenotype in a proportion
of these cells (Fig. 4d, e). Together, these data suggest that
hypoxia induces changes in ECFC phenotype suggestive of
a more adhesive, less mitotic, senescent-like phenotype.
To test this hypothesis, scratch wound assays were car-
ried out at 21 and 1% O2. Exposure of ECFCs to 1% O2decreased the wound closure rate compared with cells
grown in 21% O2, although this difference was not signifi-
cant (Fig. 5a, b). Thus, changes in ECFC cytoskeleton are
consistent with an increased adhesive capacity linked to a
reduced migratory potential in ECFCs.
ECFCs are believed to be recruited from a defined niche
into the systemic circulation, after which they home to an
area of tissue ischaemia/hypoxia where they stimulate vas-
cular repair and/or new blood vessel formation [26]. In
the in-vitro setting, tubulogenesis in Matrigel® is a robust
indicator of vasculogenic function of ECFCs growing
under normal atmospheric oxygen. Incubation of ECFCs
under normal oxygen conditions triggered tube formation
that was evident at 48 h (Fig. 6a, b). In contrast, tube area
Fig. 5 Hypoxia delays scratch wound repair and tube formation in
ECFCs. The ECFCs were grown in 21 and 1% O2. Cells were
photographed at the time of scratch and at 12 h post wounding.
a Representative images of scratch wound at time zero (0 h) and
12 hours (12 h). Bars indicate the boundaries of the scratch measured
at each time point. b Percentage migration 12-h post scratch. Each
condition was compared separately and the percentage migration
calculated for 21% O2 (empty bars) or 1% O2 (filled bars). Data plotted
as mean ± SEM of three independent experiments (n = 4)
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data suggest that hypoxia decreases ECFC-mediated tube
formation in vitro.
ECFCs are known to secrete a range of growth factors
and cytokines which have autocrine stimulatory function
[27], although it is unknown how exposure to hypoxia
influences this secretome. A profile of secreted angio-
genic factors from the conditioned medium of ECFCs
grown in 21 and 1% O2 for 24 h was identified using a
Proteome Profiler (R&D Systems). When compared with
ECFCs growing in normal atmospheric oxygen condi-
tion, hypoxia-exposed cells secreted higher levels of
VEGF and PlGF (Fig. 7a–c). Consistently, levels of PlGF
were significantly increased at 48 h when the condi-
tioned medium of ECFCs grown in 1% versus 21% O2
was analysed by ELISA (Fig. 7d). Importantly, increased
levels of PlGF were maintained in ECFCs exposed to 1%
O2 for 11 days, suggesting that PlGF secretion is not
only a short-term response to low oxygen, but is also
maintained during chronic exposure to hypoxia, which
is suggestive of an adaptive response of these cells to a
hypoxic environment (Fig. 7e).To establish whether this upregulation of PlGF oc-
curred as a result of hypoxia-induced stabilisation of
HIF-1α and other transcription factors, ECFCs were
treated with dimethyloxalylglycine (DMOG), a cell-
permeable inhibitor of prolyl hydroxylases (PHDs) that
decreases proteosomal-mediated destruction of HIF-1α.
Stabilisation of HIF-1α was observed in ECFCs grown
in 21% O2 treated with DMOG for 24 h (Fig. 8a).
Conditioned medium from DMOG-treated ECFCs also
contained higher levels of PlGF, with a higher fold-
change than that observed in ECFCs incubated in 1%
O2 versus 21% O2 (Fig. 8b). Consistent with previous data
(Figs. 4b and 6), conditioned medium from DMOG-treated
ECFCs decreased tube formation and cell viability in
ECFCs, mimicking the effect seen in 1% O2 (Fig. 8c, d).
To test whether PlGF in the conditioned medium from
ECFCs was mediating this inhibition of tube formation,
a neutralising PlGF antibody was used to inhibit PlGF in
these experiments. Exposure of ECFCs to conditioned
medium from DMOG-treated cells inhibited tube forma-
tion, as seen previously (Fig. 9, a versus b). Significantly,
incubation of conditioned medium from DMOG-treated
ECFCs with anti-PlGF neutralising antibody reversed
this inhibitory effect and returned tube formation to
control levels (Fig. 9, c versus d, e). The inclusion of an
isotype antibody control in these experiments suggests
that this effect is specifically due to the binding and in-
hibition of PlGF by the neutralising antibody (Fig. 9c).
Discussion
ECFCs remain a promising candidate for cell therapy to
treat tissue ischaemia. However, robust characterisation
of ECFC cell behaviour in the target tissues and disease-
related microenvironments is required as these cells
move towards therapy. In this study, we have defined the
response of ECFCs to hypoxia exposure, one of the main
factors associated with vascular insufficiency and tissue
ischaemia. The HIF transcription factors are considered
master regulators of hypoxia, having an established role
in the cellular response to oxygen deprivation, and are
of critical importance in hypoxia-driven angiogenesis by
controlling the expression of many genes required for
the process [28]. In response to a graded decrease in O2,
HIF-1α stabilisation was detected in ECFCs at the lower
O2 levels of 3 and 1% with no HIF stabilisation detect-
able at the higher oxygen concentrations of 5 and 10%
(Fig. 1). Similarly, in a study investigating the effect of
low oxygen levels on ECFCs and MSCs, Hofmann et al.
[29] reported that while MSCs and fibroblasts are very
sensitive to lowering oxygen concentration HIF-1α sta-
bilisation only occurred at 1% O2 levels. Accumulation
of HIF-1α occurred within 5 min in these cells (Fig. 1b).
These findings are important because the physiological
oxygen tension varies widely between different cell types
Fig. 6 Hypoxia exposure decreases ECFC angiogenesis in vitro. a ECFCs were stained with PKH membrane dye and grown in Matrigel®, and the
formation of tube-like structures was assessed after 48 h. Representative images for 21 and 1% O2 are shown. Scale bar: 100 μm. b Total tube
area (μm2) was quantified using NIS Elements software (Nikon) for ECFCs grown in 21% O2 (empty bars) or 1% O2 (filled bars). Data plotted as
mean ± SD. *p < 0.05. Scale bars: 100 μm (n = 3)
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oxygen concentration of approximately 14.5% (approxi-
mately 110 mmHg), while the brain has a much lower
physiological oxygen percentage in the region of 4.4%
(34 mmHg) [30]. In fact, culturing ECFCs in ambient
21% O2 may actually elevate the physiological oxygen
tension above baseline, where key stem cell niches such
as the bone marrow would normally experience a much
lower physiological oxygen tension of around 6.4%
(49 mmHg) [30]. Other groups have found that culturing
induced pluripotent stem cells (iPS) and mesenchymal
stem cells (MSCs) at low oxygen concentrations provides
enhanced functional outcomes [31, 32]. While not within
the remit of this study, future studies will probably define
the optimum oxygen concentration for ex-vivo ECFC cul-
ture. Maintenance in an oxygen concentration likely to be
experienced in vivo may improve the therapeutic potential
of these cells for clinical use. For this study, we chose 1%
O2 based on robust stabilisation of HIF-1α and HIF2α,
along with HIF-1α nuclear translocation and hypoxia-
dependent gene expression changes that were detected
under these conditions (Figs. 1 and 2).
ECFCs cultured in 1% O2 for 24–72 h displayed changes
in their actin cytoskeleton (Fig. 3), as well as cell doubling,
increased cell size and staining for senescence markers
(Fig. 4). Increased filamentous actin, along with the ap-
pearance of focal adhesions at the end of actin stress fi-
bres, suggested that hypoxia was inducing enhancedECFC adherence to the cell culture dish (Fig. 3). One
interpretation of these data is that when ECFCs are
recruited to the ischaemic/hypoxic tissue, they need to at-
tach to the extracellular matrix in close proximity to either
damaged blood vessels or avascular regions. These data
were supported by reduced ECFC scratch wound repair in
1% O2 versus 21% O2 (Fig. 5). Reductions in ECFC
chemotaxis/migration in response to low oxygen have
been reported by both the Yoder and Strunk groups [29,
33], while the Yoder group also detected an increase in
hypoxia-mediated tube formation in ECFCs, albeit at an
earlier time point than our study (6 h versus 72 h, Fig. 4d
[33]). Hofmann et al. [29] also report a decrease in tube
formation in ECFCs when exposed to 1% O2. In vascular
smooth muscle cells, HIF-1α expression decreased cell
migration and adherence to the ECM, with no evident
changes in vincullin or focal adhesion kinase (FAK) local-
isation [34]. Hypoxia increased MSC migration, probably
via VEGF-mediated phosphorylation of FAK and activa-
tion of MAPK and eNOS signalling [35]. Hypoxia in-
creased αvβ3 integrin cell surface expression and cell
adhesion in trophoblast stem cells [36]. Together with our
results, these data suggest that there may be cell-type spe-
cific responses to low oxygen, with ECFCs demonstrating
increased adhesiveness and decreased proliferation and
migration, perhaps to ensure their effective engraftment
to the ischaemic tissue in vivo. Consistently, we have iden-
tified that exposure of ECFCs to hypoxia decreases the
Fig. 7 Hypoxia increases secretion of PlGF in ECFCs a Conditioned medium from ECFCs grown for 48 h at 21% O2 (empty bars) or 1% O2 (filled
bars) was incubated on a human angiogenesis Proteome Profiler array to identify soluble factors secreted. Red arrow, position of PlGF on the
graph. b, c Signal intensity measured using ImageJ software, and a positive control (Ref) was used to normalise the intensity of PlGF between
conditions. d Conditioned medium from ECFCs grown in 21 and 1% O2 was probed using a PlGF-specific ELISA. PlGF concentrations were
extrapolated from a standard curve and plotted as mean ± SD. *p < 0.05. e ECFCs were grown in 1% O2 for 11 days. Conditioned medium was
harvested and PlGF levels were measured by ELISA. Data plotted as mean ± SD. **p < 0.01 (n = 3). PlGF placental growth factor
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gests that ECFCs in the hypoxic niche become more
endothelial-like to perhaps improve their ability to repair
damaged endothelium (data not shown).
One of the key findings of this study was the increased
secretion of PlGF by ECFCs (Fig. 6). Despite the robust
increase in PlGF protein expression in 1% O2 or in re-
sponse to DMOG, an inhibitor of HIF prolyl hydroxylases
[37], previous analysis of the PlGF promoter and enhancer
regions did not identify any the putative binding sites for
HIFs (hypoxia response elements (HREs)) [38–40]. Con-
sistent with data from Xiang et al. [41], we did not detect
any increase in PlGF RNA in hypoxia-exposed ECFCs. In
contrast, overexpression of HIF-1α has been reported byothers to augment the expression of PlGF in both endo-
thelial cells [42–44] and primary cardiac and vascular
cells [45], indicating that HIFs may well have a role to
play in PlGF expression. A recent report identified
novel HIF-1α HREs in intron 2 of the PlGF gene, and
highlighted chromatin remodelling via histone H3 and
H4 acetylation as a key element in HIF1α-mediated
PlGF upregulation [44, 46]. Other transcription factors
such as NFκB and CREB are also stabilised under low
oxygen conditions, and may play a role in PlGF upregu-
lation [41, 42, 45, 46]. PlGF has been reported to
enhance angiogenic signalling by acting synergistically
with VEGF to increase signalling via the receptor
VEGFR2 [47, 48] while also maintaining the ability to
Fig. 8 HIF-1α stabilisation induces PlGF expression and alters ECFC tube formation and viability. a ECFCs were grown in Matrigel® and exposed to
vehicle (DMSO, VEH) or DMOG (1 mM) for 24 h. Protein lysates were probed for HIF1α (upper panel) or β-actin (lower panel). b PlGF concentration
was measured by ELISA in conditioned medium from ECFCs treated with vehicle (DMSO) or DMOG (1 mM) for 24 h. c Conditioned medium
(CM)from ECFCs treated with vehicle (DMSO) or DMOG (1 mM) was used to treat ECFCs grown in Matrigel® and stained with PKH for 24 h. Total
tube area (μm2) quantified using NIS Elements software. d ECFCs were treated with conditioned medium from vehicle (DMSO) or DMOG (1 mM)-
treated cells for 24 h. Cell viability measured using a CCK-8 cell viability assay (Sigma), and plotted as mean % viability ± SD (n = 4). DMOG
dimethyloxalylglycine, PlGF placental growth factor. Data plotted as Mean ± SD **p < 0.01; ***p < 0.001
Fig. 9 Anti-PlGF neutralising antibody blocks DMOG-induced inhibition of ECFC tube formation. ECFCs were stained with calcein (Invitrogen) and
grown on Matrigel®. Cells were treated with conditioned medium harvested from ECFCs treated with a DMSO (vehicle) plus isotype control IgG,
b DMOG plus isotype control IgG, c DMSO plus anti-PlGF neutralising antibody or d DMOG plus anti-PlGF neutralising antibody. e At 48 h, total
tube area (μm2) was quantified using NIS Elements software (Nikon). Data plotted as mean ± SD and are representative of three independent
experiments. **p < 0.01; ***p < 0.001. Scale bars: 200 μm (n = 3). DMOG dimethyloxalylglycine, PlGF placental growth factor
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Others have identified that PlGF may increase blood
vessel formation via monocyte recruitment and para-
crine signalling to endothelial cells [41, 44]. Increased PlGF
secretion from ECFCs coincided with a delay in in-vitro
tube formation in Matrigel® (Fig. 8b, c). Neutralising
antibodies against PlGF rescue ECFC tube formation in
Matrigel® (Fig. 9). Thus, hypoxia/HIF-mediated increases
in PlGF secretion from ECFCs may inhibit tube formation
and vasculogenesis.
Our data suggest that, in vitro, in the absence of
VEGF, PlGF may not be driving ECFC tube formation,
and heterodimers of PlGF and VEGF may be the active
moieties. This is somewhat surprising, given the previ-
ously described pro-angiogenic activity of PlGF [50]. It
remains to be determined whether PlGF released from
ECFCs in the hypoxic niche would have both an auto-
crine and a paracrine function, and what the relative bal-
ance of these functions might be. We can also speculate
that PlGF from chronically hypoxia-exposed ECFCs may
function to attract monocytes, pericytes or mural cells to
stabilise the vascular niche. PlGF may also be secreted
from the cells of the tissue parenchyma in ischaemic tis-
sue. Alternatively, a paracrine source of VEGF or other
factor from cells such as pericytes or endothelial cells
may be required to trigger new blood vessel formation.
ECFCs have been demonstrated to act as paracrine me-
diators, modulating MSC regeneration potential prior to
the establishment of neovascularisation and blood perfu-
sion, ultimately enabling extensive engraftment and
long-term differentiation of transplanted MSCs [51]. Re-
cent work by Xiang et al. [41, 44] supports the idea of a
paracrine role for PlGF secreted by endothelial cells in
vascular repair.
Conclusions
This study deepens our understanding of the response of
ECFCs to hypoxia and also addresses important ques-
tions regarding the role of PlGF and chronic hypoxia in
influencing the neovascular potential of ECFCs. Further
studies will be required to determine whether ex-vivo
pre-conditioning of ECFCs, by either hypoxia or PlGF,
or manipulation of PlGF expression in vivo may be useful
tools to augment ECFC neovascularisation for the future
treatment of ischaemic disease.
Additional file
Additional file 1: Figure S1. showing characterisation of ECFC identity
using flow cytometry. ECFCs were grown in complete EBM2 medium at
21% O2. Cells were trypsinised and stained with antibodies against
endothelial markers CD31 and CD146 (green) and hematopoietic markers
CD45 and CD14 (red). Respective isotype controls are shown in black and
% positivity is shown in the bottom right-hand corner. Cell number
plotted on x axis and fluorescence intensity plotted on Y axis. Data arerepresentative of experiments carried out on at least seven ECFC clones
(n = 7). (TIF 73 kb)
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